Coeptis Therapeutics (COEP) Competitors $0.20 0.00 (0.00%) (As of 11/1/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends COEP vs. LIAN, ACXP, LPCN, NAII, ICCC, LSB, FLGC, IBIO, INKT, and BGXXShould you be buying Coeptis Therapeutics stock or one of its competitors? The main competitors of Coeptis Therapeutics include LianBio (LIAN), Acurx Pharmaceuticals (ACXP), Lipocine (LPCN), Natural Alternatives International (NAII), ImmuCell (ICCC), Lakeshore Biopharma (LSB), Flora Growth (FLGC), iBio (IBIO), MiNK Therapeutics (INKT), and Bright Green (BGXX). These companies are all part of the "pharmaceutical products" industry. Coeptis Therapeutics vs. LianBio Acurx Pharmaceuticals Lipocine Natural Alternatives International ImmuCell Lakeshore Biopharma Flora Growth iBio MiNK Therapeutics Bright Green LianBio (NASDAQ:LIAN) and Coeptis Therapeutics (NASDAQ:COEP) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, profitability, analyst recommendations, institutional ownership, earnings, valuation, dividends and community ranking. Do analysts rate LIAN or COEP? LianBio presently has a consensus target price of $3.50, indicating a potential upside of 1,106.48%. Given LianBio's higher possible upside, equities research analysts plainly believe LianBio is more favorable than Coeptis Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score LianBio 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50Coeptis Therapeutics 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Do institutionals and insiders hold more shares of LIAN or COEP? 74.8% of LianBio shares are owned by institutional investors. Comparatively, 13.9% of Coeptis Therapeutics shares are owned by institutional investors. 7.6% of LianBio shares are owned by company insiders. Comparatively, 21.5% of Coeptis Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Which has more risk and volatility, LIAN or COEP? LianBio has a beta of 0.23, meaning that its stock price is 77% less volatile than the S&P 500. Comparatively, Coeptis Therapeutics has a beta of -0.91, meaning that its stock price is 191% less volatile than the S&P 500. Does the MarketBeat Community believe in LIAN or COEP? Coeptis Therapeutics received 1 more outperform votes than LianBio when rated by MarketBeat users. Likewise, 83.33% of users gave Coeptis Therapeutics an outperform vote while only 36.36% of users gave LianBio an outperform vote. CompanyUnderperformOutperformLianBioOutperform Votes436.36% Underperform Votes763.64% Coeptis TherapeuticsOutperform Votes583.33% Underperform Votes116.67% Is LIAN or COEP more profitable? LianBio's return on equity of -33.17% beat Coeptis Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets LianBioN/A -33.17% -30.19% Coeptis Therapeutics N/A -5,710.19%-413.75% Does the media prefer LIAN or COEP? In the previous week, LianBio's average media sentiment score of 0.00 beat Coeptis Therapeutics' score of -1.00 indicating that LianBio is being referred to more favorably in the media. Company Overall Sentiment LianBio Neutral Coeptis Therapeutics Negative Which has preferable valuation & earnings, LIAN or COEP? Coeptis Therapeutics has higher revenue and earnings than LianBio. Coeptis Therapeutics is trading at a lower price-to-earnings ratio than LianBio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLianBioN/AN/A-$110.29M-$0.81-0.36Coeptis Therapeutics$80K98.31-$21.27M-$0.47-0.42 SummaryLianBio and Coeptis Therapeutics tied by winning 7 of the 14 factors compared between the two stocks. Ad Opportunistic TraderMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicted the 2020 crash a month before it happened...For a limited time, he's revealing his latest forecast here. Get Coeptis Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for COEP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart COEP vs. The Competition Export to ExcelMetricCoeptis TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$7.87M$3.15B$5.54B$8.53BDividend YieldN/A1.77%5.13%4.14%P/E Ratio-0.4211.73114.8115.14Price / Sales98.31397.851,495.55100.10Price / CashN/A148.6639.6734.08Price / Book9.904.024.665.02Net Income-$21.27M-$42.25M$119.06M$225.46M7 Day Performance-4.58%8.04%0.80%0.37%1 Month Performance20.07%8.69%5.65%3.57%1 Year Performance-79.94%32.09%36.75%29.43% Coeptis Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)COEPCoeptis Therapeutics0.4813 of 5 stars$0.20flatN/A-83.6%$7.87M$80,000.00-0.422Short Interest ↑Negative NewsGap DownLIANLianBio1.2118 of 5 stars$0.28flat$3.50+1,149.1%-92.9%$30.28MN/A-0.35110Gap UpACXPAcurx Pharmaceuticals1.2429 of 5 stars$1.89+2.7%$12.00+534.9%-63.3%$29.94MN/A-1.633Positive NewsLPCNLipocine1.5794 of 5 stars$5.55-3.8%$10.00+80.2%+137.5%$29.68M$4.80M-3.4910News CoverageNAIINatural Alternatives International1.0223 of 5 stars$4.53-5.6%N/A-24.4%$28.09M$113.80M-3.68290Analyst ForecastICCCImmuCell0.6704 of 5 stars$3.57-1.4%N/A-29.9%$27.89M$23.22M-6.7475Positive NewsLSBLakeshore Biopharma0.8251 of 5 stars$2.87-8.3%N/AN/A$26.72M$80.82M0.00773News CoverageGap UpFLGCFlora Growth2.7828 of 5 stars$1.98+7.0%$6.00+203.0%+80.4%$26.47M$76.07M0.00280Gap UpIBIOiBio1.0468 of 5 stars$2.87+0.7%$4.30+49.8%N/A$26.23M$220,000.000.00100INKTMiNK Therapeutics1.9469 of 5 stars$0.75+5.6%$9.00+1,101.6%-30.5%$26.01MN/A-1.5330News CoverageGap UpBGXXBright GreenN/A$0.14+7.9%N/A-63.5%$25.92MN/A-2.272 Related Companies and Tools Related Companies LianBio Alternatives Acurx Pharmaceuticals Alternatives Lipocine Alternatives Natural Alternatives International Alternatives ImmuCell Alternatives Lakeshore Biopharma Alternatives Flora Growth Alternatives iBio Alternatives MiNK Therapeutics Alternatives Bright Green Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:COEP) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredMusk Says ‘Dollar Will Be Worth Nothing…’Elon Musk just issued an urgent warning… It's no secret that Musk is able to move markets with his words…Crypto 101 Media | Sponsored[Just Released] Jovine's Emergency Briefing insidePeople didn't believe Jovine when he predicted the 2008 financial crisis over a year in advance. But some read...Behind the Markets | SponsoredHe made 1,303,329 in 12 months after Biden won…Tim Sykes - the world’s most apolitical Millionaire trader - just sat down for an urgent election interview… ...Timothy Sykes | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Coeptis Therapeutics Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Coeptis Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free COEP Stock Alerts